Scantox Group Publishes 2025 Annual Report, Succeeding in a Year of Dynamic Market Environment
Disciplined investment in people, science, and infrastructure positions Scantox for accelerated growth as market conditions improve.
EJBY, Denmark, May 7, 2026 — Scantox Group has today released its 2025 Annual Report, marking a year of continued revenue growth of 17%, of which 2% was organic. Reported EBITDA before special items increased to EUR 11.6m, providing an EBITDA margin of 20.9%.
This performance reflects a solid outcome in a year marked by macroeconomic headwinds, regulatory uncertainty in the US, and a constrained funding environment for biotech companies. Market conditions improved toward the end of 2025, with this positive trend carrying over into the early part of 2026.
“2025 has been a demanding year across the life science sector, and Scantox has not been immune to broader market pressures,” says Martin Amtoft-Christensen, CFO of Scantox Group. “Despite those conditions, it has been a good year for Scantox. We stayed disciplined and forward-looking, investing in our organization, expanding our capabilities, and building a strong platform for long-term development. We enter the coming years with real optimism and confidence in our ability to continue growing and creating value for our clients and partners.”
Strategic initiatives to strengthen the commercial organization delivered positive results, expanding geographical reach and broadening client segment coverage. The successful integration of the drug discovery and genetic toxicology businesses introduced a wider service offering to big pharma clients, enabling deeper engagement across the drug development process. The year also saw significant investment in a new world-class in vivo research facility, in addition to various efficiency initiatives, digitalization, and the application of AI across the Group.
“In 2025, we delivered on our strategic priorities,” says Jeanet Løgsted, CEO of Scantox Group. “Despite a challenging market, the integrations are complete, our service offering is broader than ever, and we are in a better position than ever to continue growing. The investments we made in 2025, and the capabilities we have added since, mean we are entering a new chapter for this business. Across every site and every discipline, our clients continue to choose Scantox because of the scientific rigor, quality standards, and ethical commitment we bring to every study. We are well positioned to support both new and existing clients as they advance therapies that improve lives and I am optimistic about the future of our business.”
The positive momentum has continued into 2026, with Scantox acquiring exclusive rights as the global provider of DuplexSeq™ Mutagenesis Assays for nonclinical development, a new approach methodology (“NAM”) redefining how mutagenic risk is assessed and positioning the Group at the forefront of genomic safety assessment.
The 2025 Annual Report is available here.
About Scantox:
Scantox is an integrated preclinical CRO supporting sponsors from discovery through IND-enabling nonclinical development, with operations in Denmark, Sweden, Austria, and the United Kingdom. We combine Discovery, Regulatory Toxicology, Pharmaceutical Development & Analytical, and Genetic Toxicology in one coordinated platform, helping clients generate high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines. Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology and genomic safety capabilities including Big Blue® transgenic rodent assays and DuplexSeq™ mutagenesis testing. Founded in 1977, Scantox is owned by Impilo, the leading Nordic healthcare investment company.
Press contact:
Tina Andersen, Marketing Manager Scantox Group, tia@scantox.com
